Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07329933
Recruiting Not applicable

Dexamethasone, Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy

NCT07329933 · tracked via the Priya Life Science Egypt tracker
Sponsor
Benha University
Phase
Not applicable
Started
2025-12-15
Last updated
2026-07-20

Condition(s) studied

GIT FunctionCholecystectomy, LaparoscopicDexamethasoneDexmedetomidineI-FEED Score

Investigational drug(s) / intervention(s)

Dexamethasone →Dexmedetomidine →Dexamethasone and dexmedetomidinePlacebo

Dexamethasone: Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.

Dexmedetomidine: Participants will receive Dexmedetomidine 0.5 mcg /kg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.

Dexamethasone and dexmedetomidine: Participants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg/kg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia

Placebo: Participants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia

Study summary

The goal of this clinical trial is to learn the effect of Dexamethasone and Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy

What medical problems do participants have when taking Dexamethasone and Dexmedetomidine? Researchers will compare Dexamethasone and Dexmedetomidine and Their Combination to a placebo (a look-alike substance that contains no drug) to see the effect on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.

Participants will receive Dexmedetomidine 0.5 mcg /kg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.

Participants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg/kg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.

Participants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * . Age 18-65 years. * American Society of Anesthesiologists (ASA) physical status I or II. * Scheduled for elective laparoscopic cholecystectomy surgery under general anesthesia. * Ability to provide written informed consent Exclusion Criteria: * Known allergy or contraindication to any study drug (dexamethasone, dexmedetomidine, or placebo). * Pre-existing gastrointestinal motility disorders (e.g., gastroparesis, inflammatory bowel disease). * Chronic use of opioids, steroids, or antiemetics. * History of severe cardiac disease (e.g., high-grade AV block, severe bradycardia). * Uncontrolled diabetes mellitus (HbA1c \> 8.0%). * Emergency surgery or conversion to open surgery. * Pregnancy or breastfeeding. * Morbid obesity (BMI \>40). * Severe hepatic or renal dysfunction.

Primary outcome measure(s)

  • The highest I-FEED score — 24 -48 hours post operative
    recorded daily from Postoperative Day (POD) 1 to POD 2. The I FEED score is calculated based on five components: Intake, Feeling nauseated, Emesis, Examination, and Duration of symptoms

Trial sites (1)

FacilityCityRegionStatus
Benha University Hospital Banhā Egypt Recruiting

More Benha University trials in Egypt

Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer Recruiting
Role of Urine PH in Shock Wave Lithotripsy Outcomes in Renal Stone Disease Active, not recruiting
Evaluating the Clinical Utility of Modified Ventilator-Associated Event Criteria in Predicting ICU Mortality and Ventilator Duration: Can Less Restrictive Definitions Improve Prediction? Active, not recruiting
Selective Extended Venous Stripping Versus Standard Microsurgical Varicocelectomy for Varicocele-Related Male Infertility Starting soon
Comparison Between the Effect of Two Different Doses of Oral Melatonin on Sleep Quality After Total Hip Arthroplasty Starting soon

Other trials for the same condition

Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting Recruiting
Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy Recruiting
Intraperitoneal Dexmedetomidine Versus Magnesium as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy Recruiting
Effect of Dexamethasone Adjuvant in Combined Supraclavicular Block and Suprascapular Block Versus Interscalene Block in Patients Undergoing Shoulder Arthroscopy Recruiting
Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07329933 on ClinicalTrials.gov ↗ ← All trials in Egypt